Savara Updates on Positive Phase 3 MOLBREEVI Data and BLA Submission for Autoimmune PAP

summarizeSummary

Savara Inc. filed an 8-K announcing an updated corporate presentation detailing positive Phase 3 results for MOLBREEVI and its BLA submission to the FDA for autoimmune PAP, projecting a multi-billion dollar market opportunity.

check_boxKey Events

• BLA Submission for MOLBREEVI

  Savara submitted its Biologics License Application (BLA) to the FDA in December 2025 for MOLBREEVI (molgramostim inhalation solution) for the treatment of autoimmune Pulmonary Alveolar Proteinosis (PAP).

• Positive Phase 3 IMPALA-2 Trial Results

  The corporate presentation detailed positive Phase 3 IMPALA-2 trial results, showing MOLBREEVI's superiority over placebo in primary and secondary endpoints, including DLCO% and SGRQ scores, with a well-tolerated safety profile.

• Significant Commercial Opportunity

  The company projects a U.S. total addressable market (TAM) for autoimmune PAP patients to be approximately 5,500, with a potential U.S. opportunity exceeding $2 billion, indicating 'blockbuster potential' for MOLBREEVI.

• Strong Financial Position

  Savara reported a pro forma cash position of approximately $264.4 million as of September 30, 2025, including a $140 million net equity offering in October 2025, providing a solid financial runway.

auto_awesomeAnalysis

Savara Inc. has provided a comprehensive update on its lead investigational drug, MOLBREEVI, for autoimmune Pulmonary Alveolar Proteinosis (PAP). The company's Biologics License Application (BLA) was submitted to the FDA in December 2025, a critical step towards potential market approval. The updated corporate presentation highlights strong positive Phase 3 IMPALA-2 trial results, demonstrating MOLBREEVI's superiority over placebo in key efficacy endpoints and a favorable safety profile. This progress, coupled with detailed commercialization plans and a projected U.S. market opportunity exceeding $2 billion, significantly de-risks the investment thesis and points to a substantial future revenue stream for the company.